Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

Please share Science & Enterprise

New Venture Funds to Back Life Science, Tech Start-Ups

Investor screen

Three new venture funds are seeking to invest up to $6.3 billion in start-up companies with advances in life sciences, health care, energy, and information technologies. . . . → Read More: New Venture Funds to Back Life Science, Tech Start-Ups

Real-World Data Shown to Match Eye Disease Trial Results

Fundus photograph

Research findings show data in patients’ electronic health records can be collected and analyzed to replicate results from late-stage clinical trials of an eye disease biologic drug. . . . → Read More: Real-World Data Shown to Match Eye Disease Trial Results

Nasal Spray Vaccine Shown to Stop Gonorrhea Infections

Neisseria gonorrhoeae bacteria

A vaccine against gonorrhea given as a nasal spray is shown to generate protective immune responses in lab mice of both sexes, and in females similar to an intravaginal vaccine. . . . → Read More: Nasal Spray Vaccine Shown to Stop Gonorrhea Infections

Infographic – 2022 Biotech Venture Funding Weakens

Chart: Venture investments total by year for biotech and pharma companies

Venture funds for new U.S. biotechnology and pharmaceutical companies declined from historical highs in 2022, but a closer look reveals even more signs of financial tightening. . . . → Read More: Infographic – 2022 Biotech Venture Funding Weakens

CEPI Assessing Advanced RNA Nanoparticle Vaccine

Zika virus

An international health organization is evaluating a new type of vaccine made with biodegradable RNA nanoparticles to help head off future viral pandemics. . . . → Read More: CEPI Assessing Advanced RNA Nanoparticle Vaccine

Nanotech Enzyme Process Boosts T-Cell Cancer Therapies

T-cells and cancer cells

A bioengineering team devised techniques for feasibly adding cancer-killing enzymes to engineered immune cells that in lab mice kill solid-tumor and blood cancer cells. . . . → Read More: Nanotech Enzyme Process Boosts T-Cell Cancer Therapies

BioNTech to Provide Personal Cancer Immunotherapies in UK

Vials and bottles

The biotechnology company BioNTech SE is partnering with the U.K. government to provide up to 10,000 personalized cancer immunotherapy treatments by 2030. . . . → Read More: BioNTech to Provide Personal Cancer Immunotherapies in UK

Biotech Alliance Creating Circular RNA Cancer Drug

Cancer on clipboard

A partnership of biotechnology components and therapy companies aims to develop new drugs made from circular forms of RNA, starting with a colorectal cancer treatment. . . . → Read More: Biotech Alliance Creating Circular RNA Cancer Drug

Protein Chemistry Biotech Gains Collaboration, Venture Funds

DNA molecule model

An enterprise discovering new drugs with optical light-based protein chemistry is emerging from stealth, including work with biopharmaceutical company Genentech. . . . → Read More: Protein Chemistry Biotech Gains Collaboration, Venture Funds

Trial Shows Anti-Inflammatory Drug Stops Covid-19 Hospitalization

SARS-Cov-2 virus

Findings from a clinical trial show an anti-inflammatory drug reduces new symptoms among people with Covid-19 infections and keeps them out of the hospital. . . . → Read More: Trial Shows Anti-Inflammatory Drug Stops Covid-19 Hospitalization